OncoHost

04/24/2026

🔬 It’s Medical Laboratory Professionals Week!

Here’s to the brilliant minds working behind the scenes to power precision medicine and patient care.
Thank you to our incredible lab professionals - Jim Fuller, Amir Gelman, Michael Hoxie & Macalla Tate! Your dedication to accuracy and excellence is what enables innovation to reach each patient.

04/23/2026

Our Chief Commercial Officer, Chris Dingman, took the stage to present our latest poster, highlighting the role of biological aging in predicting outcomes. The work underscores our ongoing commitment to equipping physicians with tools that bring greater clarity to complex clinical choices.

Take a closer look at the science driving the future of personalized cancer care.

04/19/2026

Attending AACR?
Don’t miss our poster presentation:
“Proteomic aging biomarkers predict survival in immunotherapy-treated tumors.”

🗓 Monday, April 20, 2026
🕘 9:00 AM – 12:00 PM (PDT)

Stop by to explore how proteomic insights are shaping the future of immunotherapy outcomes.

04/15/2026

We're proud to announce the acceptance of our abstract for presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place next week in San Diego!

This research highlights the impact of biological aging as a predictive factor for immunotherapy outcomes across multiple tumor types, including , SCLC, renal cell carcinoma (RCC), and melanoma.

Read our news release here:

PR Newswire’s news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.

04/13/2026

Our team is heading to this weekend! ✈️🔬

We’re looking forward to connecting with the global oncology community, exchanging insights, and driving the future of precision medicine through innovative biomarker-driven solutions.

See you there!

04/01/2026

Thank you MLO - Medical Laboratory Observer for spotlighting our recent publication in the Journal of Pharmaceutical and Biomedical Analysis (JPBA)!

This study introduces a validated computational method to harmonize serum and plasma proteomic datasets, overcoming longstanding analytical barriers and enabling more comprehensive biomarker research across diverse cohorts.

Read the coverage 👇

This recent study introduces a validated computational method to harmonize serum and plasma proteomic datasets, overcoming longstanding analytical barriers and enabling more comprehensi...

03/24/2026

🏆We’re proud to share that OncoHost has been named a winner in the 2026 Artificial Intelligence Excellence Awards by the Business Intelligence Group, taking top recognition in the Health category!

This award underscores what truly matters: real-world impact.

With PROphet®, our machine learning–based proteomics platform, we enable oncologists to make more precise, data-driven treatment decisions by decoding the patient’s systemic response—translating AI from promise into real-world clinical impact. 🚀

We’re grateful to the Business Intelligence Group for this recognition, and even more so to the teams across OncoHost who continue to push the boundaries of what’s possible in precision oncology.

https://prn.to/4d2Qfxe

/PRNewswire/ -- OncoHost, an AI-driven precision oncology company transforming clinical decision-making through proteomic analysis and machine learning, today...

03/23/2026

🚀 Redefining Precision Oncology with PROphet®
At OncoHost, we're not just keeping pace with innovation — we're setting the standard. The PROphet® platform is our flagship host-response profiling technology, designed to help oncologists make smarter, faster, and more personalized treatment decisions.

By analyzing proteomic patterns in patients' blood, PROphet® predicts therapeutic outcomes with unprecedented accuracy — giving physicians a powerful edge in managing complex cancers.

✅ Actionable insights
✅ AI-powered predictions
✅ Personalized patient care

The future of oncology isn’t just personalized. It’s precisely guided.
Learn more about how PROphet® is changing the game 👉

Explore OncoHost's home for cutting-edge precision oncology solutions, driving advancements in cancer care and personalized treatment strategies.

03/12/2026

Thank you MedPath for highlighting our latest research and covering this important milestone in proteomic biomarker science!

Our recently published study in the Journal of Pharmaceutical and Biomedical Analysis (JPBA) introduces a validated computational framework that harmonizes serum and plasma proteomic datasets - helping overcome a long-standing barrier in biomarker research.

By enabling reliable integration of these specimen types, this work expands the potential of existing datasets and supports more scalable, multi-cohort validation for precision oncology.

Appreciate the coverage and continued interest in advancing proteomics-driven precision oncology.
https://bit.ly/4s4SoNn

- OncoHost published a landmark study in JPBA introducing a validated computational framework that harmonizes serum and plasma proteomic datasets, overcoming a long-standing analytical barrier in biomarker research. - The multi-institutional study analyzed 7,289 proteins across 177 matched serum-pla...

03/09/2026

Have you read the latest peer-reviewed review on emerging predictive biomarkers for immunotherapy sensitivity in ?

The recently published article in ImmunoTargets and Therapy explores next-generation approaches that may help guide immunotherapy decision-making — and highlights PROphet® among the technologies contributing to this evolving landscape.

📖 Read the full review: Scan the QR code below or access the article here:
👉 https://bit.ly/4rW4cS5

02/25/2026

PROphet® is featured in a recent peer-reviewed review spotlighting next-generation predictive biomarkers shaping immunotherapy decision-making in !

📖 Read the full review: Scan the QR code below or click the link to explore the review in ImmunoTargets and Therapy:
👉 https://www.dovepress.com/emerging-predictive-biomarkers-of-immunotherapy-sensitivity-in-patient-peer-reviewed-fulltext-article-ITT

02/23/2026

We’re proud to share that PROphet® has been recognized in the latest peer-reviewed review on emerging predictive biomarkers of immunotherapy sensitivity in patients with NSCLC published by Dove Medical Press !
This comprehensive scientific article highlights cutting-edge approaches that are shaping personalized immunotherapy decision-making — and PROphet® is part of that conversation.

📖 Read the full review: Scan the QR code below or click the link to explore the review in ImmunoTargets and Therapy:
👉 https://www.dovepress.com/emerging-predictive-biomarkers-of-immunotherapy-sensitivity-in-patient-peer-reviewed-fulltext-article-ITT